ArticleJournal of neurology2022
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.Annals of clinical and translational neurology · 2022Pooled it
- Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.Neurology · 2024Trial
- Kappa Index predicts disease activity and transition to high-efficacy therapies in multiple sclerosis.Clinical chemistry and laboratory medicine · 2026Article
- HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.Journal of neurology · 2026Article
- Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry.Therapeutic advances in neurological disorders · 2026Article
- [Generalisability of Phase III Clinical Trials Using the Example of Two German Multiple Sclerosis Registries].Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2025Article
- Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.JAMA network open · 2025Article
- Health disparities in neurology.Nature reviews. Neurology · 2025Review
- Multiple sclerosis from onset to secondary progression: a 30-year Italian register study.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis.Annals of clinical and translational neurology · 2025Observational
- Observational
- The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.Journal of neurology · 2025Article
- The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis.BMC neurology · 2025Article
- No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.Biomolecules · 2025Article
- Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Protective effect of the Quercetin on experimental cuprizone-induced multiple sclerosis in male C57BL/6 mice.Current research in physiology · 2025Article
- Predictors of therapy switching to high-efficacy disease-modifying therapies in patients with multiple sclerosis: a single center, retrospective, observational study.Frontiers in neurology · 2025Article
- Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.Journal of neurology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the disease due to restrictions in reimbursement despite broader regulatory labels. Although not every patient should be treated with HE DMTs at the initial stages of the disease, early and unrestricted access to HE DMTs with a positive benefit-risk profile and a reasonable value proposition will provide the freedom of choice for an appropriate treatment based on a shared decision between expert physicians and patients. This will further optimize outcomes and facilitate efficient resource allocation and sustainability in healthcare systems and society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.